Evidence map›Paper›PMID 42903035›Full record

ArticleInternational journal of MS care2025

Wearing-Off Effect Reports in People With Multiple Sclerosis Receiving Ocrelizumab.

Sarah A Morrow, Victor Gitman, Spasojevic Sofija, Jessica Rassi, Noemi Pasquarelli, Kocho Fitovski, Galina Vorobeychik

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of MS care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sarah A MorrowDepartment of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
Victor GitmanHoffmann-La Roche, Mississauga, ON, Canada.ORCID https://orcid.org/0009-0001-4236-0114
Spasojevic SofijaHoffmann-La Roche, Mississauga, ON, Canada.ORCID https://orcid.org/0000-0001-8111-4197
Jessica RassiHoffmann-La Roche, Mississauga, ON, Canada.
Noemi PasquarelliF. Hoffmann-La Roche, Basel, Switzerland.ORCID https://orcid.org/0000-0002-4780-9056
Kocho FitovskiF. Hoffmann-La Roche, Basel, Switzerland.
Galina VorobeychikFraser Health Multiple Sclerosis Clinic, Burnaby, BC, Canada.ORCID https://orcid.org/0000-0002-5005-7158

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: A wearing-off effect has been reported in people with multiple sclerosis (MS) receiving ocrelizumab and other monoclonal antibodies. We sought to describe the real-world occurrence of wearing-off effect among people with MS in Canada treated with ocrelizumab. Methods: Canadian self-reports coded to the Medical Dictionary for Regulatory Activities preferred term Results: A total of 10,055 people with MS in Canada received 3 or more doses of ocrelizumab within COMPASS. Conclusions: A wearing-off effect was infrequently reported and did not limit treatment among people with MS in the real-world COMPASS patient support program.

Indexed as

COMPASSocrelizumabpatient reportwearing-off

Identifiers

PMID42903035
PMCPMC13629449

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.